Sarcoma spreads primarily through the vascular system: Are there biomarkers associated with vascular spread?

Clinical and Experimental Metastasis

Volumn 29, Issue 7, 2012, Pages 757-773

  Pennacchioli, Elisabetta ^a   Tosti, Giulio ^a   Barberis, Massimo ^a   De Pas, Tommaso M ^a   Verrecchia, Francesco ^a   Menicanti, Claudia ^a   Testori, Alessandro ^a   Mazzarol, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Biomarkers; Chromosomal aberrations; Expression profiling; Metastases; Sarcoma; Vascular spreading

Indexed keywords

ADAPTOR PROTEIN; AFAP1L1 PROTEIN; CAVEOLIN 1; CELL ADHESION MOLECULE; CELL PROTEIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHFR PROTEIN; CTCE 9908; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; D DIMER; DEATH ASSOCIATED PROTEIN KINASE; DYSADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EZRIN; MICRORNA; MULTIDRUG RESISTANCE PROTEIN; MYC PROTEIN; PLERIXAFOR; PROTEIN KINASE B; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMARCB1 PROTEIN; T 134 PEPTIDE; TELOMERASE; TUMOR MARKER; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ANGIOSARCOMA; BLOOD SAMPLING; BONE METASTASIS; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CIRCULATING TUMOR CELL; CLEAR CELL SARCOMA; CLINICAL EVALUATION; CONFERENCE PAPER; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HEMOSTASIS; HUMAN; KARYOTYPING; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALIGNANT FIBROUS HISTIOCYTOMA; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; METASTASIS; NONHUMAN; PLASMA CELL GRANULOMA; PROTEIN EXPRESSION; REGULATORY MECHANISM; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; LYMPHATIC SYSTEM; MICRORNAS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SARCOMA; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84868247329     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9502-4     Document Type: Conference Paper

References (100)

1. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572
2. Nguye DX, Bos PD, Massague J (2009) Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9:274-284
3. Psaila B, Lyden D (2009) The metastatic niche: Adapting the foreign soil. Nat Rev Cancer 9:285-293
4. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571-573
5. Paget S (1989) The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8:98-101
6. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820-827
7. MackalL CL, Meltzer PS, Helman LJ (2002) Focus on sarcomas. Cancer Cell 2(3):175-178
8. Jl Tolar et al (2007) Sarcoma derived from cultured mesenchymal cells. Stem Cells 25(2):371-379
9. Helman LJ, Meltzer P (2003) Mechanisms of sarcoma development. Nat Rev Cancer 3:685-694
10. Fletcher CDM, Unni KK, Mertens F et al (2002) Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon
11. Eilber FC, Dry SM (2008) Diagnosis and management of synovial sarcoma. J Surg Oncol 97:314-320
12. Clark J, Rocques PJ, Crew AJ et al (1994) Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7:502-508
13. Kawai A, Woodruff J, Healey JH et al (1998) SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338:153-160
14. Sandberg AA, Bridge JA (2002) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet 133:1-23
15. Henderson SR, Guiliano D, Presneau N et al (2005) A molecular map of mesenchymal tumors. Genome Biol 6:R76
16. Kawai A, Kondo T, Suehara Y, Kikuta K, Hirohashi S (2008) Global protein-expression analysis of bone and soft tissue sarcomas. Clin Orthop Relat Res 466(9):2099-2106
17. Ladany M, Wodruff JM, Scheithauer BW, Bridge JA, Barr FG et al (2001) Letter to editor. Re: O'Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD (2000) Malignant peripheral nerve sheath tumor with t(X;18) : A pathologic and molecular study. Mod Pathol 13:1336-1446. Mod Pathol 14(7):733-737
18. Lubieniecka JM, de Bruijn DR, Su L et al (2008) Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 68:4303-4310
19. Fernebro J, Francis P, Eden P et al (2006) Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 118:1165-1172
20. Subramanian S, Lui WO, Lee CH et al (2008) Micro-RNA expression signature of human sarcomas. Oncogene 27(14):2015-2026
21. Dela Cruz F, Matushansky I (2011) MicroRNAs in chromosomal translocation-associated solid tumors: Learning from sarcomas. Discov Med 12(65):307-317
22. Nielsen TO, West RB, Linn SC et al (2002) Molecular characterisation of soft tissue tumours: A gene expression study. Lancet 359:1301-1307
23. Ray-Coquard I, Le Cesne A, Whelan JS et al (2008) A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 13:467-473
24. Fletcher CD, Gustafson P, Rydholm A et al (2001) Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas; prognostic relevance of subclassification. J Clin Oncol 19:3045-3050
25. Beck AH, West RB, van de Rijn M (2010) Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic and predictive biomarkers. Virchows Arch 456:141-151
26. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, Socci ND, Behrendt N, Ma L, Maki RG, Pandolfi PP, Cordon-Cardo C (2007) The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13:748-753
27. Lee YF, John M, Edwards S et al (2003) Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 88:510-515
28. Lee CH, Espinosa I, Vrijaldenhoven S et al (2008) Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 14:1423-1430
29. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT (2011) Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS ONE 6(1):e14611
30. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF et al (1999) Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 24:30-34
31. Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M et al (2002) Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcomas. Cancer Res 62:2993-2998
32. Baird K, Davis S, Antonescu CR et al (2005) Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res 65:9226-9235
33. Francis P, Namlos HM, Muller C et al (2007) Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: Hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8:73
34. Singer S, Socci ND, Ambrosini G et al (2007) Gene expression profiling of liposarcoma identifies distinct biological types/ subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626-6636
35. Ugras S, Brill E, Jacobsen A, Hafner M, Socci ND, Decarolis PL, Khanin R, O'Connor R, Mihailovic A, Taylor BS, Sheridan R, Gimble JM, Viale A, Crago A, Antonescu CR, Sander C, Tuschl T, Singer S (2011) Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res 71(17):5659-5669
36. Carneiro A, Francis P, Bendahl PO, Fernebro J, Akerman M, Fletcher C, Rydholm A, Borg A, Nilbert M. Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: Different sides of a single coin? Lab Invest. 2009 Jun;89(6):668-675. Erratum in: Lab Invest (2009) 89(7):840
37. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, Singer S, Maki RG, Cordon-Cardo C (2007) Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 117(11):3248-3257
38. Linn SC, West RB, Pollack JR, Zhu S, Hernandez-Boussard T, Nielsen TO, Rubin BP, Patel R, Goldblum JR, Siegmund D, Botstein D, Brown PO, Gilks CB, van de Rijn M (2003) Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 163(6):2383-2395
39. Abbott JJ, Erickson-Johnson M, Wang X, Nascimento AG, Oliveira AM (2006) Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol 19(11):1512-1518
40. McArthur G (2007) Dermatofibrosarcoma protuberans: Recent clinical progress. Ann Surg Oncol 14(10):2876-2886
41. Lips DJ, Barker N, Clevers H, Hennipman A (2009) The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). Eur J Surg Oncol 35(1):3-10
42. Leong SP, Cady B, Jablons DM, Garcia-Aguilar J, Reintgen D, Jakub J, Pendas S, Duhaime L, Cassell R, Gardner M, Giuliano R, Archie V, Calvin D, Mensha L, Shivers S, Cox C, Werner JA, Kitagawa Y, Kitajima M (2006) Clinical patterns of metastasis. Cancer Metastasis Rev 25(2):221-232
43. Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, Brennan MF (1999) Pulmonary metastases from soft tissue sarcoma: Analysis of patterns of diseases and post metastasis survival. Ann Surg 229(5):602-610 discussion 610-612
44. Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7:737-749
45. Sleeman JP, Nazarenko I, Thiele W (2011) Do all roads lead to Rome? Routes to metastasis development. Int J Cancer 128(11):2511-2526
46. Kasthuri RS, Taubman MB, Mackman N (2009) Role of tissue factor in Cancer. JCO 27(29):4834-4838
47. Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, Busund LT, Donnem T (2010) Profiling of VEGFs and VEGFR sas prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One 5(12): E15368
48. Kalen M, Heikura T, Karvinen H, Nitzsche A, Weber H, Esser N, Yla-Herttuala S, Hellstrom M (2011) Gamma-secretase inhibitor treatment promotes VEGF-A driven blood vessel growth and vascular leakage but disrupts neovascular perfusion. PLoS ONE 6(4):e18709
49. Bray SJ (2006) Notch signalling: A simple pathway becomes complex. Nat Rev 7:678-689
50. Leong SPL, Nakakura EK, Pollock R, Chot MA, Morton DL, Henner WD, Lal A, Pillai R, Clark OH, Bacy B (2010) Unique patterns of metastases in common and rare types of malignancy. JCO 103:607-614
51. He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, Wang D (2009) Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 388(1):35-40
52. Song B, Wang Y, Xi Y et al (2009) Mechanism of chemoresistance mediated by miT-140 in human osteosarcoma and conon cancer cells. Oncogene 28(46):4065-4074
53. Song B, Wang Y et al (2010) Molecular mechanism of chemoresistence by miR-125 in osteosarcoma and colon cancer cells. Mol Cancer 30(9):96
54. Zang J, Guo W, Yang RL, Tang XD, Ji T (2010) Ewing 's sarcoma of bone: Treatment results and prognostic factors. Zhonghua Wai Ke Za Zhi 48(12):896-899
55. Lulla RR, Costa FF, Bischof JM, Chou PM, de Bonaldo M, Vanin EF, Soares MB (2011) Identification of differentially expressed micro-RNAs in osteosarcoma. Sarcoma 2011(6):1-6
56. Bianchi F, Nicassio F, Marzi M et al (2011) A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3(8):495-503
57. Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T, Cordon-Cardo C (2009) MFH classification: Differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther 9(8):1135-1144
58. Camp RK, Neumeister V, Rimm DL (2008) A decade of tissue microarrays: Progress in the discovery and validation of cancer biomarkers. J Clin Oncol 26:5630-5637
59. Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E (2010) Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer 54(1):13-18
60. Nakanishi H, Myoui A, Ochi T, Aozasa K (1997) P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 123:352-356
61. Wurl P, Meye A, Schmidt H et al (1998) High prognostic significance of MdM2/p53 co-overexpression in soft-tissue sarcomas of the extremities. Oncogene 16:1183-1185
62. Kaway A, Noguchi M et al (1994) Nuclear immunoreaction of p %£ protein in soft tissue sarcomas. A possible prognostic factor. Cancer 73:2499-2505
63. Taubert H, Meye A, Wurl P (1996) Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 56:4134-4136
64. Konomoto T, Fukuda T, Hayashi K, Kumazawa J, Tsuneyoshi M (1998) Leyomiosarcoma in soft tissue: Examination of p53 status and cell proliferating factors in different locations. Human Pathol 29:74-81
65. Antonescu CR, Leung DH et al (2000) Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications. Am J Pathol 156:977-983
66. Taubert H, Koehler T et al (2000) mdm2 mRNA level is a prognostic factor in soft tissue sarcoma. Mol Med 6:50-59
67. Oda Y, Sakamoto A, Saito T et al (2000) Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 31:185-192
68. Saito T, Oda Y et al (2000) Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 192:342-345
69. Antonescu CR, Tschernyaavsky SJ et al (2001) Prognostic impact of p53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: A molecular and clinicopathologic study of 82 cases. Clin Cancer Res 7:3977-3987
70. Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Scheider U (2001) Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol 158:833-839
71. Tomoda R, Seto M, Tsumuki H et al (2002) Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors. Cancer 95(5):1127-1133
72. Kawaguchi K, Oda Y et al (2003) Mechanisms of inactivation of the p16 gene in leyomiosarcoma of soft tissue: The absence of p16 expression correlates with the methylation status and poor prognosis. J Pathol 201:487-495
73. Oda Y, Takahira T et al (2003) Alterations of cell cycle regulators in mixofibrosarcoma with special emphasis on their prognostic implications. Human Pathol 34:1035-1042
74. Oda Y, Ohishi Y et al (2003) Nuclear expression of Y-boxbinding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 199:251-258
75. Kawaguchi K, Oda Y et al (2004) Death-associated protein kinase (DAP kinase) alteration in soft tissue leiomyosarcoma: Promoter methylation or homozygous deletion is associated with a loss of DAP kinase expression. Hum Pathol 35:1266-1271
76. Sato O, Wada T et al (2005) Expression of epidermal growth factor receptor, ERB2 and KIT in adult soft tissue sarcoma: A clinicopathologic study of 281 cases. Cancer 103:1881-1890
77. Oda Y, Yamamoto H et al (2005) Frequent alteration of p16INK4a/p14ARF and p53 pathways of round cell appearance in myxoid/round cell liposarcoma: Altered p53 gene and reduced p14ARF expression correlates with poor prognosis. J Pathol 207:410-421
78. Seidel C, Bartel F et al (2005) Alterations OD cancer-ralted genes in soft tissue sarcomas: Hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 114:442-447
79. Kobayashi C, Oda Y et al (2006) Aberrant expression of CHFR in malignant peripheral nerve sheat tumors. Mod Pathol 19:524-532
80. Izumi T, Oda Y et al (2006) Prognostic significance od dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from rhabdoid tumor. Mod Pathol 19:820-831
81. Izumi T, Oda Y, Hasegawa T et al (2007) Dysadherin expression as a significant prognosis factor and as a determinant of histologic features in synovial sarcoma: Special reference to its inverse relationship with E-cadherin expression. Am J Sur Pathol 31:85-94
82. Maeda T, Hashitani S, Zushi Y, Segawa E, Tanaka N, Sakurai K, Urade M (2008) Establishment of a nude mouse transplantable model of a human malignant fibrous histiocytoma of the mandible with high metastatic potential to the lung. J Cancer Res Clin Oncol 134(9):1005-1011
83. Oda Y, Tateishi N, Matono H, Matsuura S, Yamamaoto H, Tamiya S, Yokoyama R, Matsuda S, Iwamoto Y, Tsuneyoshi M (2009) Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer 124(8):1852-1859
84. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, Dumollard JM, Haudebourg J, Leroux A, Mainguené C, Terrier P, Chibon F, Coindre JM, Pedeutour F (2009) Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15(18):5696-5703
85. Tsiatis AC, Herceg ME, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Cates JM (2009) Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Mod Pathol 22(11): 1432-1438
86. Dreux N, Marty M et al (2010) Value and limitation of immunohistochemical expression of HMGA2in mesenchymal tumors: About a series of 1052 cases. Mod Pathol 23(12):1657-1666
87. Shim BY, Yoo J, Lee YS, Hong YS, Kim HK, Kang JH (2010) Prognostic role of Rb, p16, cyclin D1 proteins in soft tissue sarcomas. Cancer Res Treat 42(3):144-150
88. Lahat G, Tuvin D, Wei C, Wang WL, Pollock RE, Anaya DA, Bekele BN, Corely L, Lazar AJ, Pisters PW, Lev D (2010) Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: A tissue microarray-based study. Ann Oncol 21(5):1112-1120
89. Lahat G, Zhang P, Zhu QS, Torres K, Ghadimi M, Smith KD, Wang WL, Lazar AJ, Lev D (2011) The expression of c-Met pathway components in unclassified pleomorphic sarcoma/ malignant fibrous histiocytoma (UPS/MFH): A tissue microarray study. Histopathology 59(3):556-561
90. Torres KE, Liu J et al (2011) Activated MET is a prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumor. Clin Cancer Res 17(12):3943-3955
91. Furu M, Kajita Y, Nagayama S, Ishibe T, Shima Y, Nishijo K, Uejima D, Takahashi R, Aoyama T, Nakayama T, Nakamura T, Nakashima Y, Ikegawa M, Imoto S, Katagiri T, Nakamura Y, Toguchida J (2011) Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas. Oncogene 30(38):4015-4025
92. Carneiro A, Bendahl PO, Akerman M, Domanski HA, Rydholm A, Engellau J, Nilbert M (2011) Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. J Clin Pathol 64(8):689-694
93. Gasparini P, Facchinetti F et al (2011) Prognostic determinants in epithelioid sarcoma. Eur J Cancer 47(2):287-295
94. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W, Aglietta M (2005) Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 11(2 Pt 1):490-497
95. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, Hwang ST, Khanna C, Helman LJ (2008) Inhibition of the CXCR4/ CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 25(3):201-211
96. Strahm B, Durbin AD, Sexsmith E, Malkin D (2008) The CXCR4-SDF1 alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis 25(1):1-10
97. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A et al (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15:350-362
98. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP (2008) Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med 6(6):23
99. Suehara Y (2011) Proteomic analysis of soft tissue sarcoma. Int J Clin Oncol. 16(2):92-100
100. Lofti R, Eisenbacher J, Solgi G, Fuchs K, Yildiz T, Nienhaus C, Rojewski MT, Schrezenmeier H (2011) Human mesenchymal stem cells (MSCs) respond to native but not oxidized damage associated molecular pattern molecules (DAMPs) from necrotic (tumor) material. Eur J Immunol 41:2021-2028